Literature DB >> 10389992

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.

J H de Wilt1, E R Manusama, S T van Tiel, M G van Ijken, T L ten Hagen, A M Eggermont.   

Abstract

An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24-26 degrees C, anti-tumour effects were lost, whereas temperatures of 38-39 degrees C or 42-43 degrees C resulted in higher response rates. However, at 42-43 degrees C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 microg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38 degrees C was mandatory. Moreover, the dose of TNF could be lowered to 10 microg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389992      PMCID: PMC2362986          DOI: 10.1038/sj.bjc.6690335

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Authors:  H R Alexander; D L Bartlett; S K Libutti; D L Fraker; T Moser; S A Rosenberg
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.

Authors:  C Benckhuijsen; B B Kroon; A N van Geel; J Wieberdink
Journal:  Eur J Surg Oncol       Date:  1988-04       Impact factor: 4.424

3.  Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Sone; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

5.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

6.  Serum-free in vitro bioassay for the detection of tumor necrosis factor.

Authors:  S M Kramer; M E Carver
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

7.  Chemotherapy of sarcomas of the limbs by regional perfusion.

Authors:  E T Krementz; R D Carter; C M Sutherland; I Hutton
Journal:  Ann Surg       Date:  1977-05       Impact factor: 12.969

8.  Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.

Authors:  M R de Vries; I H Borel Rinkes; C J van de Velde; T Wiggers; R A Tollenaar; P J Kuppen; A L Vahrmeijer; A M Eggermont
Journal:  Recent Results Cancer Res       Date:  1998

9.  Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.

Authors:  I H Borel Rinkes; M R de Vries; A M Jonker; T J Swaak; C E Hack; P T Nooyen; T Wiggers; A M Eggermont
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

Authors:  P T Nooijen; E R Manusama; A M Eggermont; L Schalkwijk; J Stavast; R L Marquet; R M de Waal; D J Ruiter
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

View more
  15 in total

Review 1.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.

Authors:  W K de Roos; J H de Wilt; M E van Der Kaaden; E R Manusama; M W de Vries; A Bout; T L ten Hagen; D Valerio; A M Eggermont
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

Review 3.  TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.

Authors:  Xiaohang Liu; Wei Wu; Ligang Fang; Yingxian Liu; Wei Chen
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 4.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

5.  20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.

Authors:  Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Johannes H W de Wilt; Jacobus W A Burger; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

6.  TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Authors:  A H van der Veen; J H de Wilt; A M Eggermont; S T van Tiel; A L Seynhaeve; T L ten Hagen
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 7.  Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Curr Treat Options Oncol       Date:  2007-12-08

8.  The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion model.

Authors:  Joerg Pelz; Marco Mollwitz; Christian Stremmel; Jonas Goehl; Arno Dimmler; Werner Hohenberger; Thomas Meyer
Journal:  BMC Cancer       Date:  2004-08-23       Impact factor: 4.430

9.  Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.

Authors:  T L M ten Hagen; S Hoving; G Ambagtsheer; S T van Tiel; A M M Eggermont
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

10.  Nifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusion.

Authors:  O Thews; M Hummel; D K Kelleher; B Lecher; P Vaupel
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.